Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients

Vasaturo,Fortunata; Solai,Fabiana; Malacrino,Carolina; Nardo,Tiziana; Vincenzi,Bruno; Modesti,Mauro; Scarpa,Susanna

doi:10.3892/ol.2012.977

Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients

Authors:
- Fortunata Vasaturo
- Fabiana Solai
- Carolina Malacrino
- Tiziana Nardo
- Bruno Vincenzi
- Mauro Modesti
- Susanna Scarpa
View Affiliations

Affiliations: Department of Emergency, University Sapienza, Rome I-00161, Italy, Department of Surgical Sciences, University Sapienza, Rome I-00161, Italy, Department of Experimental Medicine, University Sapienza, Rome I-00161, Italy, Department of Medical Oncology, University Campus Bio-Medico, Rome I-00161, Italy
Published online on: October 17, 2012 https://doi.org/10.3892/ol.2012.977
Pages: 316-320

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes involved in the process of tumor invasion and metastasis that are found throughout tissues and also in the plasma. The aim of this study was to investigate whether the evaluation of plasma concentrations of MMPs 2, 3 and 9 may have clinical significance in breast cancer. Therefore, sera obtained from 80 patients with breast neoplasia (50 carcinomas and 30 fibroadenomas) were collected before and 96 h after surgery and the concentrations of MMPs 2, 3 and 9 were quantified using an enzyme-linked immunosorbent assay (ELISA). The mean expression level of MMP 2 was significantly higher in carcinoma compared with that in fibroadenoma patients, while there was no significant difference for MMPs 3 and 9. In addition, the group of carcinoma patients was analyzed in order to compare the mean values for each MMP obtained before and after surgery. However, the differences between pre- and post-surgery values for all three MMPs were not statistically significant. Furthermore, the plasma levels of each MMP were correlated with certain clinicopathological parameters of the tumors and we observed a significant and direct correlation between the concentrations of MMPs 2 and 9 and tumor histological grade. These data suggest that the quantification of plasma MMP 2 and MMP 9 levels may provide additional clinical information of the tumor and it is, therefore, a possible prognostic index for breast cancer.

View Figures

View References

1	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
2	Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, et al: Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer. 2:204–207. 2000. View Article : Google Scholar : PubMed/NCBI
3	Liotta LA: Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46:1–7. 1986.PubMed/NCBI
4	Lynch CC and Matrisan LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation. 70:561–573. 2002. View Article : Google Scholar : PubMed/NCBI
5	Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J and Somiari RI: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 233:98–107. 2006. View Article : Google Scholar : PubMed/NCBI
6	Leppä S, Saarto T, Vehmanen L, Blomqvist C and Elomaa I: A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 10:1057–1063. 2004.PubMed/NCBI
7	Mendes O, Kim HT and Stoica G: Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 22:237–246. 2005. View Article : Google Scholar : PubMed/NCBI
8	Baker EA, Stephenson TJ, Reed MW and Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol. 55:300–304. 2002. View Article : Google Scholar : PubMed/NCBI
9	Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Matrix metalloproteinases in neoplasm-induced extracellular matrix remodelling in breast carcinoma. Anticancer Res. 21:2021–2028. 2001.PubMed/NCBI
10	González LO, Pidal I, Junquera S, Corte MD, Vásquez J, Rodríguez JC, Lamelas ML, Merino AM, García-Muñíz JL and Vizoso FJ: Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 97:957–963. 2007.PubMed/NCBI
11	Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 83:1153–1162. 1998. View Article : Google Scholar : PubMed/NCBI
12	Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15:RA32–RA40. 2009.PubMed/NCBI
13	Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol. 26:1363–1368. 2005.PubMed/NCBI
14	Staack A, Badendieck S, Schnorr D, Loening SA and Jung K: Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 6:192006. View Article : Google Scholar : PubMed/NCBI
15	Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di Trapani D, Gebbia N and Leto G: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastasis to the bone. Anticancer Res. 27:1519–1525. 2007.PubMed/NCBI
16	Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M and Matache C: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 10:499–510. 2006. View Article : Google Scholar : PubMed/NCBI
17	Stankovic C, Konjevic G, Gopcevic K, Jovic V, Inic M and Jurisic V: Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract. 206:241–247. 2010. View Article : Google Scholar : PubMed/NCBI
18	Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E and Giannelli G: MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res. 27:3593–3600. 2007.
19	Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessement of prognosis in breast cancer patients. Int J Cancer. 106:745–751. 2003. View Article : Google Scholar : PubMed/NCBI
20	Köhrmann A, Kammerer U, Kapp M, Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 9:1882009.PubMed/NCBI
21	Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ and Shao ZM: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 88:75–85. 2004. View Article : Google Scholar : PubMed/NCBI
22	Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat. 58:287–293. 1999.PubMed/NCBI
23	Talvensaari-Mattila A, Pääkko P, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat. 65:55–61. 2001. View Article : Google Scholar
24	Atik E, Akansu B, Bakaris S and Aban N: Expression of cyclooxygenase-2 and its relation to histological grade, inducible nitric oxide synthase, matrix metalloproteinase-2, CD-34, Caspase-3, and CD8 in invasive ductal carcinoma of the breast. Saudi Med J. 31:130–134. 2010.
25	Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G and Cohen C: COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol. 15:255–259. 2007. View Article : Google Scholar : PubMed/NCBI
26	Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A and Turpeenniemi-Hujanen T: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 89:215–220. 2005. View Article : Google Scholar : PubMed/NCBI
27	de la Torre J, Sabadell MD, Rojo F, Lirola JL, Salaricru S, Reventos J, Ramón y Cajal S and Xercavins J: Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome. Eur J Obstet Gynecol Reprod Biol. 151:72–76. 2010.PubMed/NCBI